SAN FRANCISCO – With the recent Agenus Inc. deal in immuno-oncology "adding a new dimension to our discovery engine" and phase III rheumatoid arthritis winner baricitinib likely to generate "a lot of news this year," Incyte Corp. will welcome a pair of brand new clinical candidates in oncology to its pipeline this year, CEO Herve Hoppenot told attendees of the J.P. Morgan Healthcare Conference.